Clinical Research Directory
Browse clinical research sites, groups, and studies.
Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial
Sponsor: Ain Shams University
Summary
The goal of this randomized crossover clinical trial is to compare the efficacy and safety of Silodosin versus Tamsulosin in patients with moderate to severe lower urinary tract symptoms due to Benign Prostatic Hyperplasia. The main questions it aims to answer are: Does Silodosin provide superior improvement in symptom scores (IPSS) compared to Tamsulosin? Is there a difference in safety profile and adverse events between the two treatments? Researchers will compare both treatments in a crossover design, where each participant receives both medications in different periods without a washout phase, to evaluate individual response differences. Participants will: Receive both study medications in different periods according to random allocation. Undergo periodic assessment of urinary symptoms and quality of life. Perform routine follow-up evaluations including symptom scoring and urine flow measurements.
Official title: : Efficacy of Silodosin Versus Tamsulosin in Patients With Moderate to Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Randomized Crossover Clinical Trial
Key Details
Gender
MALE
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-03-22
Completion Date
2026-10-22
Last Updated
2026-03-16
Healthy Volunteers
No
Interventions
Silodosin
Silodosin 8 mg oral capsule administered once daily for 4 weeks during the assigned treatment period.
Tamsulosin
Tamsulosin 0.4 mg oral capsule administered once daily for 4 weeks during the assigned treatment period.
Locations (1)
Ain Shams University Hospitals, Urology Outpatient Clinic
Cairo, Egypt